Clinical research of the prediction of clinical outcome in patients with metastatic colorectal cancer treated with cetuximab

Clinical research of the prediction of clinical outcome in patients with metastatic colorectal cancer treated with cetuximab - IBACET study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004993

Enrollment

Registered

2011-02-01

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histological confirmation of colorectal cancer 2) To receive cetuximab alone or cetuximab combination therapy between July 2008 and December 2009 3) To stored in tissue sections of primary or metastatic lesions

Exclusion criteria

Exclusion criteria: 1) Unable to assess the efficacy of cetuximab treatment 2) Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Progression-free survival and Overall survival	—

Secondary

Measure	Time frame
Response rate, Grade 3 and more adverse events rate of interest to cetuximab	—

Countries

Japan

Contacts

Public ContactToshikazu Moriwaki

Tsukuba University Hospital Gastroenterology

tmoriwak@md.tsukuba.ac.jp

Outcome results